A Study to Determine Appropriate Dosage for Vapor Therapy and Other Ablative Therapies to Treat Cancerous Prostate and Kidney Tissue
About this study
The study objectives are to determine the appropriate dosage for vapor therapy and other ablative therapies to treat cancerous prostate and kidney tissue.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
- Subjects with the ability to understand and consent to releasing their extirpated prostate or kidney for use in this study, if required by the site.
- Prostates with a confirmed biopsy demonstrating adenocarcinoma removed via a radical prostatectomy.
- Prostates with biopsy confirmed recurrent adenocarcinoma removed via a salvage radical prostatectomy.
- Prostates with or without cancer that have been removed via a radical cystoprostatectomy or pelvic exenteration.
- Kidneys removed via a total or partial nephrectomy – no enucleations will be used.
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Lance Mynderse, M.D.
Contact us for the latest status
Lance Mynderse M.D.